|Other Names||Nicotinamide riboside kinase 2, NRK 2, NmR-K 2, Integrin beta-1-binding protein 3, Muscle integrin-binding protein, MIBP, Nicotinic acid riboside kinase 2, Ribosylnicotinamide kinase 2, RNK 2, Ribosylnicotinic acid kinase 2, NMRK2, ITGB1BP3, NRK2|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2791a was selected from the N-term region of human ITGB1BP3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR) to form nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN). Reduces laminin matrix deposition and cell adhesion to laminin, but not to fibronectin. Involved in the regulation of PXN at the protein level and of PXN tyrosine phosphorylation. May play a role in the regulation of terminal myogenesis.|
|Tissue Location||Predominantly expressed in skeletal muscle and, at a much lower level, in the heart (at protein level). No expression in brain, kidney, liver, lung, pancreas nor placenta|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
ITGB1BP3 catalyzes the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR) to form nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN). The protein reduces laminin matrix deposition and cell adhesion to laminin, but not to fibronectin. It is involved in the regulation of PXN at the protein level and of PXN tyrosine phosphorylation and may play a role in the regulation of terminal myogenesis.
Bieganowski,P., Cell 117 (4), 495-502 (2004)Li,J., J. Cell Biol. 147 (7), 1391-1398 (1999)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.